Echo Therapeutics (ECTE/$1.9 | Price Target: $8.5) Nathan Cali email@example.com | (561) 994-5723 Buying a First in Class Opportunity at a Discount
Rating: BUY On June 8th 2012 the American Diabetes Association 72nd Scientific Session will take place in Philadelphia ; More than 14,000 scientists, physicians and other healthcare professionals from around the globe will gather to share cutting edge research Echo Therapeutics is expected to present data from "Symphony", a leading continuous glucose monitoring device; oral presentation to demonstrate mechanism of action efficiencies, accuracy, safety, in type 1/2 diabetic patients in a clinic setting Also on June 8th, data from a comparative analysis will be reported comparing the three FDA approved CGM devices; Medtronic (MDT: Not Rated) Minimed Guardian, Abbott Labs (ABT: Not Rated) Freestyle Navigator, Dexcom (DXCM: Not Rated) Seven Pl In our view, Echo's device is superior based upon the demonstrated combination of safety and efficacy, cost estimates, ease of use, and targeted market opportunity (only non-invasive device, no CGM device approved in hospital) Buy, price target $8.50; trading at a significant discount (~90%) compared to that of a pure play competitor DexCom (DXCM: Not Rated); low technology risk product proof-of-concept demonstrated, data from IDE study 2012, CE mark approval expected 2013
Let's see-now a marketing manager and now high visibility of presentation. Sounds bullish to me. Sounds like preparing for future partners like Ferndale only bigger partners like Abbott or JJ. Hey Bayer did you hear about the company that got away? Would like to see them at derm conferences as soon as approval.